Increased Scrutiny for Telehealth Prescribers and Lilly's Compounding Concerns
Telehealth prescribers are now under heightened scrutiny following FDA warnings about compounded weight loss drugs, while Lilly is actively opposing certain compounding practices.
Recent developments indicate that telehealth prescribers may face intensified scrutiny, particularly those linked to companies the FDA has warned regarding the marketing of compounded weight loss drugs.
In a related matter, Lilly is reportedly taking a stand against compounding practices that it views as problematic, signifying a push to regulate these practices more strictly.
Additionally, CVS has reinstated Lilly's obesity drug to its formularies, marking a significant shift in the availability of this treatment option.
Updates
Update at 13:26 UTC on 2026-05-28
STAT reported In this morning's Pharmalittle roundup, we're reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more.
Sources: STAT